Society for Cardiovascular Angiography Interventions (SCAI)

The Society for Cardiovascular Angiography and Interventions (SCAI) represents interventional cardiology through education, advocacy, research, setting guidelines and quality patient care. SCAI provides thought leadership in cath lab procedures, new technology and policy.

Simpsons Interventions, a California-based healthcare technology company, has received the FDA’s breakthrough device designation for its Acolyte Image Guided Crossing and Re-Entry Catheter System. SCAI released the list of its late-breaking clinical study trials at its 2022 annual meeting. #SCAI #SCAI22 #SCAI2022

Links to all the SCAI 2022 late-breaking clinical research

The Society for Cardiovascular Angiography and Interventions (SCAI) has announced its late-breaking study presentations at its 2022 Scientific Sessions. 

June 8, 2022
Early clinical evaluation of the Alleviant System to create no-implant interatrial shunts to treat heart failure patients with preserved and reduced ejection fraction (HFpEF and HFrEF) demonstrated procedural safety and feasibility with a promising efficacy signal through six months.

Key interventional cardiology takeaways from the SCAI 2022 conference

The key interventional cardiology takeaways from sessions presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2022 annual meeting.

June 7, 2022
SCAI 2022 interventional cardiology TAVR CTO PCI TPV cath labs

TPV valves, CTO PCI and more: SCAI 2022 updates for interventional cardiologists

The first two days of SCAI 2022 were jam-packed with innovative technologies and late-breaking research.

May 20, 2022
heart.png

New guidelines detail PFO management, including when to consider closure

The new guidance document was designed to provide helpful information on a topic "surrounded by controversy." 

May 20, 2022
Kirk Garratt, past SCAI president, explains the impact of the iodine contrast shortage on interventional cardiology and the cath lab. #SCAI

VIDEO: How the iodine contrast shortage is impacting interventional cath labs

Kirk Garratt, MD, medical director of the Center for Heart and Vascular Health, ChristianaCare, and a past president of SCAI, explains what this shortage means for interventional cardiologists.

May 19, 2022
Intravascular lithotripsy (IVL) Shockwave Medical PCI PAD CAD trial prsented at SCAI 2022. #DisruptPAD, #DisruptCAD, #SCAI #SCAI22 #SCAI2022

Intravascular lithotripsy tied to superior long-term PAD, PCI outcomes at SCAI 2022

Two separate sessions presented at SCAI 2022 focused on long-term outcomes associated with Shockwave Medical's IVL technology.

May 19, 2022
 U.S. Senate has confirmed cardiologist Robert Califf as next FDA commissioner. 

Cardiologists join the FDA’s fight against menthol cigarettes, flavored cigars

The American College of Cardiology (ACC), Association of Black Cardiologists, American Heart Association and Society for Cardiovascular Angiography & Interventions are just some of the healthcare organizations supporting the FDA's proposal.

May 13, 2022
Several ACC 2022 late-breaking trials may have impacts on clinical practice for interventional cardiology and structural heart. One trial compared FFR vs. IVUS guided PCI for intermediate coronary lesions. Photos by Dave Fornell

Key interventional cardiology takeaways from ACC.22

Several late-breaking clinical trials at ACC.22 will likely impact clinical practice. Below are summaries of a few key trials and their takeaways for interventional cardiology and structural heart interventions. 

April 11, 2022

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Trimed Popup
Trimed Popup